Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Sperm Dna Quality Predicts Intrauterine Insemination Outcome: A Prospective Cohort Study, Eyup Duran, M. Morshedi, S. Taylor, S. Oehninger
Sperm Dna Quality Predicts Intrauterine Insemination Outcome: A Prospective Cohort Study, Eyup Duran, M. Morshedi, S. Taylor, S. Oehninger
Eyup Hakan Duran
BACKGROUND: We aimed to investigate whether sperm DNA quality may predict intrauterine insemination (IUI) outcome. METHODS: The study was designed in a prospective cohort fashion, at a tertiary centre for reproductive medicine. A total of 119 patients underwent 154 cycles of IUI. Parameters related to demography, cycle management and semen sample used for IUI were evaluated. Conventional semen parameters, morphology (strict criteria), sperm DNA fragmentation and stability [evaluated by terminal deoxynucleotidyl transferase-mediated dUDP nick-end labelling (TUNEL) and acridine orange staining under both acid and acid + heat denaturing conditions respectively] were measured. The main outcome measure was clinical pregnancy, defined …
The Impact Of A Gonadotropin-Releasing Hormone Antagonist On Gonadotropin Ovulation Induction Cycles In Women With Polycystic Ovary Syndrome: A Prospective Randomized Study, L. Stadtmauer, A. Sarhan, Eyup Duran, H. Beydoun, S. Bocca, B. Pultz, S. Oehninger
The Impact Of A Gonadotropin-Releasing Hormone Antagonist On Gonadotropin Ovulation Induction Cycles In Women With Polycystic Ovary Syndrome: A Prospective Randomized Study, L. Stadtmauer, A. Sarhan, Eyup Duran, H. Beydoun, S. Bocca, B. Pultz, S. Oehninger
Eyup Hakan Duran
OBJECTIVE: To evaluate the effect of the gonadotropin-releasing hormone antagonist Ganirelix on gonadotropin ovulation induction (OI) in patients with polycystic ovary syndrome (PCOS). DESIGN: Prospective, randomized, controlled study. SETTING: Academic infertility center. PATIENT(S): Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles. INTERVENTION(S): Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was >/=13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI. MAIN OUTCOME MEASURE(S): Per cycle clinical pregnancy rate (CPR), live-birth rate (LBR), total gonadotropin dose, days of stimulation, serum LH and peak …